325 related articles for article (PubMed ID: 12006512)
1. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia.
Frankel AE; Powell BL; Hall PD; Case LD; Kreitman RJ
Clin Cancer Res; 2002 May; 8(5):1004-13. PubMed ID: 12006512
[TBL] [Abstract][Full Text] [Related]
2. Reducing anti-DT IgG concentrations to improve the efficacy of a diphtheria fusion protein.
Hall PD; Beagle KL; Garrett-Mayer E; Frankel AE
Anticancer Drugs; 2008 Nov; 19(10):1007-11. PubMed ID: 18827566
[TBL] [Abstract][Full Text] [Related]
3. Antibody response to DT-GM, a novel fusion toxin consisting of a truncated diphtheria toxin (DT) linked to human granulocyte-macrophage colony stimulating factor (GM), during a phase I trial of patients with relapsed or refractory acute myeloid leukemia.
Hall PD; Virella G; Willoughby T; Atchley DH; Kreitman RJ; Frankel AE
Clin Immunol; 2001 Aug; 100(2):191-7. PubMed ID: 11465948
[TBL] [Abstract][Full Text] [Related]
4. Diphtheria toxin-interleukin-3 fusion protein (DT(388)IL3) prolongs disease-free survival of leukemic immunocompromised mice.
Black JH; McCubrey JA; Willingham MC; Ramage J; Hogge DE; Frankel AE
Leukemia; 2003 Jan; 17(1):155-9. PubMed ID: 12529673
[TBL] [Abstract][Full Text] [Related]
5. Toxicology and pharmacokinetics of DTGM, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony-stimulating factor, in cynomolgus monkeys.
Hotchkiss CE; Hall PD; Cline JM; Willingham MC; Kreitman RJ; Gardin J; Latimer A; Ramage J; Feely T; DeLatte S; Tagge EP; Frankel AE
Toxicol Appl Pharmacol; 1999 Jul; 158(2):152-60. PubMed ID: 10406930
[TBL] [Abstract][Full Text] [Related]
6. Induction of apoptosis in multidrug-resistant and radiation-resistant acute myeloid leukemia cells by a recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor.
Perentesis JP; Waddick KG; Bendel AE; Shao Y; Warman BE; Chandan-Langlie M; Uckun FM
Clin Cancer Res; 1997 Mar; 3(3):347-55. PubMed ID: 9815691
[TBL] [Abstract][Full Text] [Related]
7. A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors: a report of the Children's Cancer Group.
Cairo MS; Krailo MD; Weinthal JA; Secola R; Bergeron S; van de Ven C; Blazar BR; Garrison L; Reaman GH
Cancer; 1998 Oct; 83(7):1449-60. PubMed ID: 9762948
[TBL] [Abstract][Full Text] [Related]
8. High-level expression and purification of the recombinant diphtheria fusion toxin DTGM for PHASE I clinical trials.
Frankel AE; Ramage J; Latimer A; Feely T; Delatte S; Hall P; Tagge E; Kreitman R; Willingham M
Protein Expr Purif; 1999 Jun; 16(1):190-201. PubMed ID: 10336877
[TBL] [Abstract][Full Text] [Related]
9. Cell-specific modulation of drug resistance in acute myeloid leukemic blasts by diphtheria fusion toxin, DT388-GMCSF.
Frankel AE; Hall PD; McLain C; Safa AR; Tagge EP; Kreitman RJ
Bioconjug Chem; 1998; 9(4):490-6. PubMed ID: 9667951
[TBL] [Abstract][Full Text] [Related]
10. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors.
Feuring-Buske M; Frankel AE; Alexander RL; Gerhard B; Hogge DE
Cancer Res; 2002 Mar; 62(6):1730-6. PubMed ID: 11912147
[TBL] [Abstract][Full Text] [Related]
11. Production of recombinant DTctGMCSF fusion toxin in a baculovirus expression vector system for biotherapy of GMCSF-receptor positive hematologic malignancies.
Williams MD; Rostovtsev A; Narla RK; Uckun FM
Protein Expr Purif; 1998 Jul; 13(2):210-21. PubMed ID: 9675065
[TBL] [Abstract][Full Text] [Related]
12. Diphtheria toxin-murine granulocyte-macrophage colony-stimulating factor-induced hepatotoxicity is mediated by Kupffer cells.
Westcott MM; Abi-Habib RJ; Cohen KA; Willingham MC; Liu S; Bugge TH; Leppla SH; Frankel AE
Mol Cancer Ther; 2004 Dec; 3(12):1681-9. PubMed ID: 15634662
[TBL] [Abstract][Full Text] [Related]
13. In vivo biotherapy of HL-60 myeloid leukemia with a genetically engineered recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor.
Perentesis JP; Gunther R; Waurzyniak B; Yanishevski Y; Myers DE; Ek O; Messinger Y; Shao Y; Chelstrom LM; Schneider E; Evans WE; Uckun FM
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2217-27. PubMed ID: 9815618
[TBL] [Abstract][Full Text] [Related]
14. Acute myeloid leukemia cells in G0 phase of the cell cycle that are unresponsive to conventional chemotherapy are sensitive to treatment with granulocyte-macrophage colony-stimulating factor/diphtheria toxin fusion proteins.
Jedema I; Barge RM; Frankel AE; Willemze R; Falkenburg JH
Exp Hematol; 2004 Feb; 32(2):188-94. PubMed ID: 15102480
[TBL] [Abstract][Full Text] [Related]
15. Toxicology and pharmacokinetics of DT388-GM-CSF, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony-stimulating factor (GM-CSF) in C57BL/6 mice.
Hall PD; Kreitman RJ; Willingham MC; Frankel AE
Toxicol Appl Pharmacol; 1998 May; 150(1):91-7. PubMed ID: 9630457
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
Cragg LH; Andreeff M; Feldman E; Roberts J; Murgo A; Winning M; Tombes MB; Roboz G; Kramer L; Grant S
Clin Cancer Res; 2002 Jul; 8(7):2123-33. PubMed ID: 12114412
[TBL] [Abstract][Full Text] [Related]
18. Interstitial diphtheria toxin-epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice.
Liu TF; Hall PD; Cohen KA; Willingham MC; Cai J; Thorburn A; Frankel AE
Clin Cancer Res; 2005 Jan; 11(1):329-34. PubMed ID: 15671563
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of diphtheria-growth factor fusion proteins is enhanced by co-administration of cytosine arabinoside in an immunodeficient mouse model of human acute myeloid leukemia.
Hogge DE; Feuring-Buske M; Gerhard B; Frankel AE
Leuk Res; 2004 Nov; 28(11):1221-6. PubMed ID: 15380349
[TBL] [Abstract][Full Text] [Related]
20. Diphtheria toxin fused to variant interleukin-3 provides enhanced binding to the interleukin-3 receptor and more potent leukemia cell cytotoxicity.
Liu TF; Urieto JO; Moore JE; Miller MS; Lowe AC; Thorburn A; Frankel AE
Exp Hematol; 2004 Mar; 32(3):277-81. PubMed ID: 15003313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]